Axelsson S - Search Results

1

Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.

Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R. Axelsson S, et al. Diabetes Care. 2013 Nov;36(11):3418-24. doi: 10.2337/dc12-2251. Epub 2013 Jul 17. Diabetes Care. 2013. PMID: 23863909 Free PMC article. Clinical Trial.

2

GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.

Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Akerman L, Casas R; Clinical GAD-Study Group in Sweden. Ludvigsson J, et al. Among authors: axelsson s. Diabetes Metab Res Rev. 2014 Jul;30(5):405-14. doi: 10.1002/dmrr.2503. Diabetes Metab Res Rev. 2014. PMID: 24302596 Clinical Trial.

3

GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.

Pihl M, Barcenilla H, Axelsson S, Chéramy M, Åkerman L, Johansson I, Ludvigsson J, Casas R. Pihl M, et al. Among authors: axelsson s. Clin Immunol. 2017 Mar;176:114-121. doi: 10.1016/j.clim.2017.01.010. Epub 2017 Jan 26. Clin Immunol. 2017. PMID: 28131926 Clinical Trial.

4

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E, Mallone R, Ludvigsson J, Casas R. Axelsson S, et al. PLoS One. 2011;6(12):e29008. doi: 10.1371/journal.pone.0029008. Epub 2011 Dec 12. PLoS One. 2011. PMID: 22174945 Free PMC article.

5

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD₆₅-induced immune response.

Tavira B, Cheramy M, Axelsson S, Åkerman L, Ludvigsson J, Casas R. Tavira B, et al. Among authors: axelsson s. Diabetologia. 2017 Jul;60(7):1276-1283. doi: 10.1007/s00125-017-4263-x. Epub 2017 Mar 29. Diabetologia. 2017. PMID: 28357504 Free PMC article. Clinical Trial.

6

GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R. Hjorth M, et al. Among authors: axelsson s. Clin Immunol. 2011 Jan;138(1):117-26. doi: 10.1016/j.clim.2010.10.004. Epub 2010 Nov 1. Clin Immunol. 2011. PMID: 21044870 Clinical Trial.

7

Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).

Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R. Axelsson S, et al. Diabetes Metab Res Rev. 2010 Oct;26(7):559-68. doi: 10.1002/dmrr.1126. Diabetes Metab Res Rev. 2010. PMID: 20830731

8

Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children.

Axelsson S, Faresjö M, Hedman M, Ludvigsson J, Casas R. Axelsson S, et al. Cryobiology. 2008 Dec;57(3):201-8. doi: 10.1016/j.cryobiol.2008.08.001. Epub 2008 Aug 12. Cryobiology. 2008. PMID: 18761006

9

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. Ludvigsson J, et al. Among authors: axelsson s. N Engl J Med. 2008 Oct 30;359(18):1909-20. doi: 10.1056/NEJMoa0804328. Epub 2008 Oct 8. N Engl J Med. 2008. PMID: 18843118 Clinical Trial.

10

Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.

Pihl M, Akerman L, Axelsson S, Chéramy M, Hjorth M, Mallone R, Ludvigsson J, Casas R. Pihl M, et al. Among authors: axelsson s. Clin Exp Immunol. 2013 Jun;172(3):394-402. doi: 10.1111/cei.12078. Clin Exp Immunol. 2013. PMID: 23600827 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results